24/02/2017
Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss
Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that theUS Food and Drug Administration(FDA) has granted [...]
